Cardima PMA for Treatment of Atrial Fibrillation Symptoms to Be Reviewed by FDA Dispute Resolution Panel

FREMONT, CA -- (MARKET WIRE) -- March 22, 2007 -- Cardima, Inc. (OTCBB: CRDM), a medical device
company focused on the treatment of atrial fibrillation, announced today
that the U.S. Food and Drug Administration (FDA) will convene a dispute
resolution panel on April 19, 2007 to consider the approvability of
Cardima's pre-market approval application (PMA) for the REVELATION® Tx
Microcatheter System for the treatment of symptoms associated with atrial
fibrillation. The Medical Device Dispute Resolution Panel (MDDRP) will be
comprised of medical experts who will advise the FDA in its evaluation of
the safety and effectiveness of the REVELATION® Tx Microcatheter System.

Gabe Vegh, Chief Executive Officer of Cardima, said, "We are pleased to
have this opportunity to openly discuss the scientific issues with a panel
of experts who are familiar with the rapidly evolving field of atrial
fibrillation, and we are hopeful that the experts can help resolve the
dispute regarding our PMA. We believe that our clinical data demonstrate
sufficient safety and effectiveness to warrant marketing approval, and we
are thankful to the experts who have agreed to assist us in presenting our
data to the panel."

About Cardima

Cardima, Inc. has developed the REVELATION® Tx, REVELATION® T-Flex and
REVELATION® Helix linear ablation microcatheters, the NAVIPORT®
deflectable guiding catheters, and the INTELLITEMP® energy management
system for the minimally invasive treatment of atrial fibrillation. The
REVELATION® Tx, REVELATION® T-Flex and REVELATION® Helix systems and
the INTELLITEMP® have received CE Mark approval in Europe. The Company
has also developed and obtained marketing clearance in the USA for a
Surgical Ablation System, which is used by cardiac surgeons to ablate
cardiac tissue during heart surgery using radio frequency (RF) energy. For
more information please visit the Company's website at
http://www.cardima.com.

Forward-Looking Statements

The statements in this press release that are not descriptions of
historical facts are forward-looking statements that are subject to risks
and uncertainties. These include statements included in this press release
related to Cardima's amendment to its PMA for treating symptoms of atrial
fibrillation including the expected time period for the FDA's review of
that amendment and the possibility of receiving approval for the treatment,
all of which are prospective. Such statements are only predictions and
reflect the Company's expectations and assumptions as of the date of this
press release based on currently available operating, financial, and
competitive information. The actual events or results may differ materially
from those projected in such forward-looking statements due to a number of
factors, including risks involved with Cardima's ability to obtain
regulatory approval in the United States for its Ablation System for use in
treating the symptoms of atrial fibrillation within its anticipated
timeframes, if at all; risks associated with the Company's ability to
successfully commercialize its Cardiac Ablation System in the United States
and elsewhere if its Cardiac Ablation System is approved for use in the
United States; risks associated with the Company's dependence on patents
and proprietary rights; risks associated with the Company's protection and
enforcement of its patents and proprietary rights; risks associated with
the development or availability of competitive products or technologies;
and the other risks and uncertainties identified in the Company's filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. The Company expressly
disclaims any intent or obligation to update any of these forward-looking
statements.